First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA pet
First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA pet
复制标题
DOI：
10.1002/hed.20418
复制
发表时间：
2006-09-01
影响因子：
2.9
通讯作者：
Harada, Tamotsu
中科院分区：
文献类型：
--
作者：
Aihara, Teruhito;Hiratsuka, Junichi;Harada, Tamotsu
背景我们研究了硼中子俘获治疗（BNCT）在胶质母细胞瘤和黑色素瘤以外的合适癌症中的应用，因此选择头颈部恶性肿瘤作为适应性癌症。我们报告了我们的第一例治疗的临床结果，并讨论了应用BNCT头颈部肿瘤的几个优点。患者为一名48岁女性，患有复发性颌下腺癌。我们在BNCT之前通过氟-18-标记的对硼苯丙氨酸正电子发射断层扫描（F-18-BPA PET）证实了肿瘤对硼苯丙氨酸（BPA）的积聚能力。肿瘤/正常组织硼浓度比为2.9。使用“SERA”软件程序对患者进行了照射前CT扫描，以制定治疗计划。肿瘤在京都大学研究反应堆用超热中子5兆瓦照射90分钟。肿瘤剂量为20.0 ~ 25.2戈伊，正常组织剂量为3.2 ~ 5.8戈伊。到目前为止，有连续完全消退的肿瘤，没有急性和慢性并发症的1.5年。虽然只有1例患者显示完全消退，并且需要额外的长期随访来评估这种治疗，但我们相信头颈部肿瘤适合BNCT，并且这种优异的结果将在不久的将来对患者产生巨大影响。(c)2006 Wiley Periodicals，Inc.
Background. We investigated the application of boron neutron capture therapy (BNCT) to suitable cancers other than glioblastoma and melanoma, Head and neck malignancies were consequently selected as adaptable cancers. We reported the clinical results of our first case treated and discussed several advantages to the application of BNCT to head and neck tumors.Methods. The patient was a 48-year-old woman with recurrent submandibular gland cancer. We confirmed the p-boronophenylalanine (BPA)-accumulating capacity of the tumor by fluorine-18-labeled p-boronophenylaianine positron emission tomography (F-18-BPA PET) before BNCT. The tumor/normal tissue boron concentration ratio was 2.9. The patient underwent a preirradiation CT scan for treatment planning performed using the "SERA" software program. The tumor was irradiated at the Kyoto University Research Reactor with epithermal neutrons 5 MW for 90 minutes. The tumor dose and normal tissue dose calculated ranged from 20.0 to 25.2 Gy and from 3.2 to 5.8 Gy, respectively.Results. To date there has been continuous complete regression in the tumor and no acute and chronic complications for 1.5 years.Conclusions. Although only 1 patient has shown complete regression and additional long-term follow-up should be required to assess this treatment, we believe that head and neck tumors are suitable for BNCT and that such excellent results will have a great impact on patients in the near future. (c) 2006 Wiley Periodicals, Inc.